Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 208

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 208
---
 these unaudited condensed consolidated financial statements.

F-2

Liminatus Pharma, Inc. (Succesor to Iris Parent Holding Corp.) Condensed Consolidated Statements of Operations (Unaudited)

| ​                                                       
 ​                                                       | ​ 
 ​ | ​                                    
 For the three months ended March 31, 
 ​                                    |     ​ 
  2025 | ​ | ​ |     ​ 
  2024 |
|:--------------------------------------------------------|:--|:-------------------------------------|------:|:--|:--|------:|
| Franchise tax expense                                   | ​ | $                                    |   255 | ​ | $ |   247 |
| Loss from operations                                    | ​ |                                      |  -255 | ​ |   |  -247 |
| ​                                                       | ​ | ​                                    |     ​ | ​ | ​ |     ​ |
| Net loss                                                | ​ | $                                    |  -255 | ​ | $ |  -247 |
| ​                                                       | ​ | ​                                    |     ​ | ​ | ​ |     ​ |
| Weighted average shares outstanding - basic and diluted | ​ |                                      |   100 | ​ |   |   100 |
| ​                                                       | ​ | ​                                    |     ​ | ​ | ​ |     ​ |
| Basic and diluted net loss per share                    | ​ | $                                    | -2.55 | ​ | $ | -2.47 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3

Liminatus Pharma, Inc. (Succesor to Iris Parent Holding Corp.) Condensed Consolidated Statements of Changes in Stockholder’s Deficit (Unaudited) For the Three Months Ended March 31, 2025 and 2024

| ​                 
 ​                 
 ​                 
 ​                 | ​ 
 ​ 
 ​ |            ​ 
 Common Stock 
            ​ 
       Shares | ​ 
 ​ | ​      
 ​      
 Amount | ​ 
 ​ | ​ 
 ​ 
 ​ | ​                  
 ​                  
 Additional Paid in 
 Capital            |  ​ 
  ​ | ​ 
 ​ 
 ​ | ​                  
 ​                  
 Stock Subscription 
 Receivable         |   ​ 
   ​ | ​ 
 ​ 
 ​ | ​                   
 ​                   
 Accumulated Deficit |    ​ 
    ​ 
    ​ | ​ 
 ​ 
 ​ | ​             
 ​             
 Stockholder’s 
 Deficit       |    ​ 
    ​ |
|:------------------|:--|-------------: